R148
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 109
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.370
- MYC_TARGETS_V1+0.340
- PANCREAS_BETA_CELLS+0.330
- PROTEIN_SECRETION+0.330
- ANDROGEN_RESPONSE+0.310
- UV_RESPONSE_DN+0.240
- XENOBIOTIC_METABOLISM+0.220
- ESTROGEN_RESPONSE_LATE+0.200
- TGF_BETA_SIGNALING+0.200
- ADIPOGENESIS+0.170
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.590
- INTERFERON_GAMMA_RESPONSE-0.450
- IL6_JAK_STAT3_SIGNALING-0.340
- MITOTIC_SPINDLE-0.250
- MYOGENESIS-0.250
- ALLOGRAFT_REJECTION-0.230
- APICAL_JUNCTION-0.180
- DNA_REPAIR-0.180
- KRAS_SIGNALING_DN-0.170
- COMPLEMENT-0.160
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-BH-A1EN-01A-11R-A13Q-07 | — | C | 0.806 |
| 2 | SRR10899980 | — | — | 0.785 |
| 3 | C3L-01632 | — | cohortA4 | 0.739 |
| 4 | 0177d00d-7d3f-43c8-8d0f-e6333e73efa4 | — | — | 0.737 |
| 5 | BS_TBWYAFSM | EPN | EPN Tumor | 0.731 |
| 6 | R72 | — | — | 0.715 |
| 7 | 4ea93d27-97e3-40bd-8734-d026e48fbbe4 | — | — | 0.708 |
| 8 | BS_TBWYAFSM | Spinal Cord Ependymoma | — | 0.707 |
| 9 | DRR168541 | — | — | 0.704 |
| 10 | SRR8518238 | — | C | 0.699 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.370 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.340 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.330 | Cobimetinib | — uncovered |
| PROTEIN_SECRETION | 0.330 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.310 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.240 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.220 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.200 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.200 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.170 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.170 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.170 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.150 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.150 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.150 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.140 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.130 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.130 | Inavolisib | — uncovered |
| COAGULATION | 0.100 | Binimetinib | — uncovered |
| PEROXISOME | 0.100 | Idelalisib | — uncovered |